First PCSK9 Inhibitor approved by FDA

By Sue Ann Syoen, R.Ph.
Vice President, Client Services

As an update to last month’s article regarding PCSK9 inhibitors, named for their mechanism of action, being introduced to the U.S. market. These new category of biologic agents used for the treatment of hypercholesterolemia. The FDA has approved the first monoclonal antibody in the lipotropic class called Proprotein Convertase Subtilisin/Kexin Type 9, or PCSK9. The estimated annual cost is $14,500.

Daklinza (daclatasvir)

The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. This is the first drug, among the new breed of anti-HCV molecules with the potential for cure, that is indicated for genotype 3 infections.

Technivie (ombitasvir)

The FDA approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.

Odomzo (sonidegib)

The FDA has approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.

Odomzo is a pill taken once a day. It works by inhibiting a molecular pathway, called the Hedgehog pathway, which is active in basal cell cancers. By suppressing this pathway, Odomzo may stop or reduce the growth of cancerous lesions.

For Benefit Plan Administrators

This document is provided as information only and should not be used solely as a decision making tool for benefit plan changes. Please consult with your Account Manager to discuss potential impacts and benefit plan changes.

For questions or more information please contact your 4D Pharmacy Management Account Manager

The information contained in this document is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.

4Dpharmacy.com